Pieris Pharmaceuticals, Inc.
Symbole: PIRS
NASDAQ
11.08
USDPrix du marché aujourd'hui
-0.5788
Ratio P/E
0.0000
Ratio PEG
13.70M
Cap MRK
- 0.00%
Rendement DIV
Pieris Pharmaceuticals, Inc. (PIRS) États financiers
Bilan
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 174.43 | 26.4 | 59.2 | 117.8 | |||||||||||
balance-sheet.row.short-term-investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.net-receivables | 11.07 | 6 | 5.8 | 3.3 | |||||||||||
balance-sheet.row.inventory | 2.1 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 37.14 | 6.3 | 8.4 | 6.5 | |||||||||||
balance-sheet.row.total-current-assets | 224.75 | 38.7 | 73.4 | 127.6 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 42.47 | 0 | 20.7 | 23 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0.65 | 0 | 1.4 | 2.9 | |||||||||||
balance-sheet.row.total-non-current-assets | 43.11 | 0 | 22.1 | 25.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.account-payables | 22.5 | 3.4 | 4.2 | 8.6 | |||||||||||
balance-sheet.row.short-term-debt | 14.09 | 0 | 0.9 | 1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 24.12 | 0 | 12.2 | 13.8 | |||||||||||
Deferred Revenue Non Current | 12.49 | 0 | 18.7 | 38.4 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -12.49 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 36.07 | 8.6 | 10.7 | 15.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 36.6 | 0 | 31 | 52.2 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 37.32 | 0 | 12.2 | 13.8 | |||||||||||
balance-sheet.row.total-liab | 154.63 | 11.9 | 67.6 | 102.8 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.37 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.retained-earnings | -1228.58 | -315 | -290.4 | -257.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.87 | 0 | -0.3 | 0.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1342.3 | 341.6 | 318.5 | 307 | |||||||||||
balance-sheet.row.total-stockholders-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 267.86 | - | - | - | |||||||||||
Total Investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.total-debt | 37.32 | 0 | 13.1 | 13.8 | |||||||||||
balance-sheet.row.net-debt | -97.65 | -17.4 | -25.5 | -103.9 |
Tableau des flux de trésorerie
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1.81 | 1.8 | 2.8 | 2.4 | |||||||||||
cash-flows.row.deferred-income-tax | 14.53 | -4.5 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 3.35 | 3.3 | 4.4 | 5.2 | |||||||||||
cash-flows.row.change-in-working-capital | -48.14 | -48.1 | -33.4 | 30.5 | |||||||||||
cash-flows.row.account-receivables | 5.31 | 5.3 | -2.6 | -1.8 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 5.7 | |||||||||||
cash-flows.row.account-payables | -0.79 | -0.8 | -4.2 | 7 | |||||||||||
cash-flows.row.other-working-capital | -12.71 | -52.7 | -26.5 | 19.6 | |||||||||||
cash-flows.row.other-non-cash-items | -0.82 | 18.3 | -0.5 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -53.82 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.acquisitions-net | -12.17 | 0 | 20.2 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -22.84 | -22.8 | -48.4 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 35.01 | 35 | 28.2 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 12.17 | 0 | -20.2 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 12 | 12 | -21.2 | -0.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -1 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 19.74 | 19.8 | 6.9 | 57.1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.07 | 0.1 | 1.3 | 2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 19.8 | 19.8 | 7.2 | 59.1 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.78 | 0.8 | -5.2 | -3.2 | |||||||||||
cash-flows.row.net-change-in-cash | -21.24 | -21.2 | -79.1 | 47.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 134.97 | 17.4 | 38.6 | 117.8 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 156.21 | 38.6 | 117.8 | 70.4 | |||||||||||
cash-flows.row.operating-cash-flow | -53.82 | -53.8 | -59.9 | -7.7 | |||||||||||
cash-flows.row.capital-expenditure | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.free-cash-flow | -53.99 | -54 | -61 | -8.6 |
Row du compte de résultat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 42.81 | 42.8 | 25.9 | 31.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 6.49 | 1.8 | 2.8 | 2.4 | |||||||||||
income-statement-row.row.gross-profit | 36.32 | 41 | 23.1 | 29.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 41.8 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 16.85 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.operating-expenses | 55.04 | 56.9 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 55.04 | 58.7 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.interest-income | 1.85 | 1.9 | 0.7 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 3.94 | 1.8 | 8.2 | 3.7 | |||||||||||
income-statement-row.row.ebitda-caps | 3.87 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -30.74 | -15.8 | -43.5 | -51.8 | |||||||||||
income-statement-row.row.income-before-tax | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
income-statement-row.row.income-tax-expense | 12.28 | 0 | -2 | -2.4 | |||||||||||
income-statement-row.row.net-income | -23.67 | -24.5 | -31.3 | -43.4 |
Questions fréquemment posées
Quel est le total de Pieris Pharmaceuticals, Inc. (PIRS) de l'actif total?
Pieris Pharmaceuticals, Inc. (PIRS) Le total des actifs est 38680000.000.
Quel est le revenu annuel de l'entreprise?
Le revenu annuel est 20819000.000.
Quelle est la marge bénéficiaire de l'entreprise?
La marge bénéficiaire de l'entreprise est 0.848.
Quel est le flux de trésorerie disponible de l'entreprise?
Le flux de trésorerie disponible est -43.657.
Quelle est la marge bénéficiaire nette de l'entreprise?
La marge bénéficiaire nette est -0.553.
Quel est le revenu total de l'entreprise?
Le revenu total est -0.718.
Qu'est-ce que Pieris Pharmaceuticals, Inc. (PIRS) bénéfice net (revenu net)?
Le bénéfice net (revenu net) est -24543000.000.
Quel est l'endettement total de l'entreprise?
La dette totale est 0.000.
Quel est le montant des dépenses d'exploitation?
Les dépenses d'exploitation sont 56873000.000.
Quel est le montant de la trésorerie de l'entreprise?
Les liquidités de l'entreprise sont 17396000.000.